Published in AIDS Weekly, February 6th, 2006
According to a recent report from Luxembourg, "Our study aimed to complete the published data on ARV therapy in Africa by describing the baseline situation in Rwanda before the launch of a large ARV program (ESTHER).
"Prescription habits, frequency and reasons for treatment interruptions but also antiviral efficacy, resistance to ARVs, and genotypic variability of the viruses present in Rwanda were analyzed."
"Among the 233 patients included in the study," the authors reported, "it appeared that a vast majority (91%) were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-02-06)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.